GSK sets the stage for a toe-to-toe market showdown with Gilead's HIV champion Truvada

ViiV Healthcare and majority owner GlaxoSmithKline have cleared another important hurdle on a long-running quest to challenge Gilead’s dominance in preventative HIV treatments.